Nuvectis Pharma, Inc. reports developments as a clinical-stage biopharmaceutical company focused on precision medicines for serious oncology indications. Company news centers on NXP900, an oral small-molecule inhibitor of the SRC Family of Kinases, including SRC and YES1, and on clinical and preclinical work in genetically or molecularly defined cancer settings.
Recurring updates include financial results, business highlights, clinical program progress, AACR and other oncology conference presentations, pharmacokinetic and pharmacodynamic findings, drug-drug interaction data, and combination-therapy research in non-small cell lung cancer and other advanced solid tumors. News also covers capital resources and financing activity tied to development operations.
Nuvectis Pharma (NVCT) reported Phase 1b NXP200 responses in patients with recurrent or progressive BRAF V600-mutated gliomas.
At the May 4, 2026 cutoff, 27 patients were efficacy-evaluable. Objective response rates were 40.0% in 20 high-grade and 42.9% in seven low-grade glioma patients, using RANO 2.0 brain-tumor response criteria. High-grade patients had three complete responses, one preliminary; low-grade patients had one confirmed complete response. Median response duration was 6.97 months in high-grade glioma and had not been reached in low-grade glioma. Median overall survival was 17.15 months and not reached, respectively.
Among 28 safety-evaluable patients, 14.3% had Grade 3 or higher treatment-related adverse events; none caused discontinuation or death. Nuvectis expects to submit a U.S. investigational new drug application for NXP200 by year-end 2026.
Nuvectis Pharma (NVCT) will participate in the Maxim Growth Summit 2026 in New York on October 14, 2026. Chairman and CEO Ron Bentsur will join the Immunology & Inflammation Therapies panel at 10:30 AM ET. A webcast of the panel discussion will be available in the Investors section of the company’s website.
Nuvectis Pharma (NVCT) announced NXP200 received Breakthrough Therapy Designation in China for BRAF V600-mutant recurrent or progressive high-grade glioma. China’s Center for Drug Evaluation granted the designation to the investigational oral, brain-penetrant BRAF inhibitor, also known as HSK42360.
Nuvectis in-licensed exclusive worldwide rights to NXP200 outside Greater China from Haisco Pharmaceutical Group in June 2026. The company reports single-agent clinical activity in primary central nervous system tumors and other cancers, including in patients previously treated with BRAF inhibitors. Nuvectis plans a U.S. investigational new drug submission in the fourth quarter of 2026.
Nuvectis Pharma (NVCT) will participate in two upcoming investor conferences in September 2026 to discuss its clinical-stage pipeline in complement-related diseases and oncology.
The company joins the 2026 Cantor Global Healthcare Conference for a fireside chat on Friday, September 11, 2026 at 9:10 AM ET, and the H.C. Wainwright 28th Annual Global Investment Conference for a company presentation on Monday, September 14, 2026 at 12:00 PM ET. Webcasts for both events will be accessible through links provided by the organizers and via the Investors section of Nuvectis’ website.
Nuvectis is developing ciprocopan (NXP100), a complement Factor B inhibitor and its lead candidate, recently approved in China for treating PNH patients previously untreated with complement inhibitors, as a once-daily oral option for complement-mediated diseases. Its oncology pipeline also includes NXP200, an oral brain-penetrant BRAF inhibitor targeting BRAF V600X and non-V600 mutations, and NXP900, an oral inhibitor of SRC family kinases SRC and YES1 intended to comprehensively block SRC signaling.
Nuvectis Pharma (NASDAQ: NVCT) reported second quarter 2026 results and major pipeline and financing updates. The company completed in-licensing of ex-China rights to two Haisco compounds, ciprocopan (NXP100), a once-daily oral Complement Factor B inhibitor, and NXP200, a brain-penetrant paradox-breaker BRAF inhibitor, positioning Nuvectis as a late-stage clinical development organization.
Haisco obtained July 2026 marketing approval in China for ciprocopan in PNH patients not previously treated with complement inhibitors, with a second PNH indication under review. Nuvectis plans a pre-IND FDA meeting and IND submission for ciprocopan and an IND for NXP200 in 4Q 2026. A $115 million follow-on offering in July 2026, anchored by healthcare investors, is expected to extend the cash runway into 1H 2029. Q2 2026 net loss was $7.0 million on R&D expenses of $4.7 million and G&A of $2.5 million, with June 30, 2026 cash of $22.2 million before the offering.
Nuvectis (NASDAQ: NVCT) announced that ciprocopan (NXP100), a once-daily oral complement Factor B inhibitor, received marketing approval from China’s NMPA for treating Paroxysmal Nocturnal Hemoglobinuria (PNH) patients previously untreated with complement inhibitors.
The approval is based on a head-to-head Phase 3 trial versus Soliris (eculizumab) in treatment-naive PNH patients, in which ciprocopan met all primary and secondary endpoints and showed superior efficacy and favorable safety. Haisco developed and will commercialize ciprocopan in China, while Nuvectis holds exclusive rights outside Greater China, India and certain Southeast Asian countries.
Nuvectis Pharma (NASDAQ: NVCT)/b) reported that ciprocopan (NXP100), a once-daily oral Complement Factor B inhibitor, received marketing approval from China’s NMPA for treating Paroxysmal Nocturnal Hemoglobinuria (PNH) patients previously untreated with complement inhibitors.This is the first global approval of a once-daily oral Factor B inhibitor and is based on a head-to-head Phase 3 trial versus Soliris in treatment‑naive PNH patients, where ciprocopan met all primary and secondary endpoints, showed superior hemoglobin responses and transfusion avoidance, and had no discontinuations due to adverse events. Haisco developed and controls ciprocopan in China, while Nuvectis holds exclusive rights outside Greater China, India and parts of Southeast Asia.
Nuvectis Pharma (Nasdaq: NVCT) priced an underwritten public offering of 5,000,000 common shares at $20.00 per share, targeting $100 million in gross proceeds, plus a 30-day option for 750,000 additional shares.
Proceeds will fund NXP100, NXP200, NXP900, hiring, capital spending and general corporate purposes.
Nuvectis Pharma (Nasdaq: NVCT) announced it has commenced an underwritten public offering of common stock, with all shares offered by the company and a 30-day option for underwriters to purchase up to an additional 15% of shares.
Proceeds are planned to fund NXP100, NXP200, NXP900 development, hiring, capital expenditures, public-company costs, and general corporate purposes.
Nuvectis (NASDAQ: NVCT) signed a license agreement with Haisco for exclusive ex-China rights to two clinical-stage assets: Complement Factor B inhibitor NXP100 and paradox-breaker BRAF inhibitor NXP200.
The deal adds late-stage programs in complement-mediated diseases and oncology, with patents to 2042–2043 and up to $1.461B in potential payments plus tiered royalties, subject to financing conditions.